BSD answers FDA’s questions on MicroThermX
This article was originally published in Clinica
Executive Summary
BSD Medical has provided further information on the 510(k) application for its Phase II MicroThermX microwave ablation system (MTX-180), as requested by the US FDA. The MTX-180 uses microwave energy to ablate soft tissue via a single-patient-use disposable antenna, and is designed to treat cancer. BSD originally filed the application in March, but the agency replied with questions earlier this month. Salt Lake City, Utah-based BSD described this as a “routine part” of the review process, and now says it is optimistic about the outcome of the application. The company’s Phase I MicroThermX Microwave Ablation System (MTX-100) received 510(k) approval in September 2008.